Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

BioAge Labs (BIOA) Cash from Operations (2023 - 2026)

BioAge Labs' Cash from Operations history spans 2 years, with the latest figure at 28251000.0 for Q4 2025.

On a quarterly basis, Cash from Operations fell 449.84% to 28251000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 81627000.0, a 58.43% decrease, with the full-year FY2025 number at 81627000.0, down 58.43% from a year prior.
Cash from Operations hit 28251000.0 in Q4 2025 for BioAge Labs, down from 16044000.0 in the prior quarter.
Over the last five years, Cash from Operations for BIOA hit a ceiling of 5138000.0 in Q4 2024 and a floor of 28251000.0 in Q4 2025.